Abstract
Glycation is recognized for its ability to stiffen collagen matrices through non-enzymatic crosslinking. However, the biological effects of glycation in vivo, particularly in diabetic hyperglycemia remain less understood. Clinical observations suggest that diabetes contributes to pathogenic tumor vasculature, yet the underlying mechanisms are not clear. Here, we employed in vitro hydrogels, an ex ovo chicken chorioallantoic membrane model, a mouse model, and RNA sequencing to demonstrate how diabetic hyperglycemia impacts tumor vasculature barrier integrity via glycation-mediated ECM stiffening and production of advanced glycation end products. Stiffened ECM and activated AGE-RAGE signaling lead to heightened contractility, activation of NF-κB, increased secretion of GM-CSF in tumor cells, and subsequently, impaired tumor vasculature barrier function. Our findings reveal a novel mechanism by which matrix stiffness and AGE-RAGE signaling synergistically govern vasculature barrier integrity and highlight a key role for matrix stiffness in NF-κB activity.
Keywords:
AGE-RAGE; Diabetic hyperglycemia; GM-CSF; NF-kB; Non-enzymic glycation; endothelial barrier function.